“Solidarity Trial”: A Feeling of Trust Towards COVID-19 Treatments
Corona Virus Disease (COVID-19) drugs are not being developed at the pace in which the disease is spreading throughout the world. WHO and its partners have announced the worldwide clinical trial on 18th March 2020, known as “Solidarity Trial” for greater co-ordination of developments of drugs. “Solidarity Trialis an international clinical trial to help find an effective treatment for COVID-19”. The trial is randomized, open-label and adaptive. This trial will analyze four treatment options against standard of care, after recruiting patients from various countries, and then will approach to their relative effectiveness against the disease. The aim of this trial is to rapidly explore if any of the administered drugs will slow progression of disease or improve survival.
The rationale of conducting “Solidarity Trial” is to reduce time taken by the trials. Randomized clinical trials generally take years to conduct, while, “Solidarity Trial” will reduce the duration by 80%. By enrolling patients from around the world, this trial might be able to provide result more rapidly than multiple small trials. Moreover, those small multiple trials will not be able to gather solid evidence required to determine the relative effectiveness of given unproven drugs.
Mullard A. Flooded by the torrent: the COVID-19 drug pipeline. Lancet. 2020;395(10232):1245- 46. PMID: 32305088. DOI: https://doi.org/10.1016/S0140-6736(20)30894-1
World Health Organization. “Solidarity” clinical trial for COVID-19 treatments [Internet]. WHO: Geneva; 2020 March. [cited 2020 May 7]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments [Internet].Science; 2020 Mar 22. [cited 2020 May 8]Available from:https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments
Wang BCY, Wen D, Liu W, Wang J, Fan G, Ruan L, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382(19):1787-99.Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
Copyright (c) 2020 Naresh Karki
This work is licensed under a Creative Commons Attribution 4.0 International License.
- The Journal of Lumbini Medical College (JLMC) publishes open access articles under the terms of the Creative Commons Attribution (CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- JLMC requires an exclusive licence to publish the article first in its journal in print and online.
- The corresponding author should read and agree to the following statement before submission of the manuscript for publication,
- License agreement
- In submitting an article to Journal of Lumbini Medical College (JLMC) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JLMC are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. If the law requires that the article be published in the public domain, I/we will notify JLMC at the time of submission, and in such cases the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication waiver.
- I, and all co-authors, agree that, if the article is editorially accepted for publication in JLMC, data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.
Please visit Creative Commons web page for details of the terms.